Kaiser Permanente Medical Center

San Francisco, California 94118

0 studies enrolling now · 20 studies all time

What they study most

Arthritis, Carcinoma, Non-Small-Cell Lung, Chronic Hepatitis B, Chronic Hepatitis C Infection, Coronary Artery Disease, Epithelial Ovarian Cancer, Fallopian Tube Cancer, HIV Infections, Heart Failure, Hepatitis C Virus, Hepatitis C Virus (HCV), Hepatitis C, Genotype 1

Studies at this site

• TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure — Completed
• Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients — Completed
• Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV — Stopped early
• Prospective Observational Epidemiologic Study of Maraviroc's Safety — Completed
• Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip — Stopped early
• VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer — Completed
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed
• Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection — Completed
• Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II) — Completed
• Positive Choice: Prevention for Positive Health — Completed
• Expanded Access Program for Maraviroc At Multiple Centers — Completed
• Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus — Completed
• Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients — Completed
• Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment — Completed
• Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 — Completed
• Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism — Completed
• TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer — Completed
• Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer — Completed
• Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection — Stopped early
• A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection — Stopped early